result preview expect
remain restrict bayer due role anim health dispos may publish
forecast continu oper target price rate
result thursday feb uk time earn call uk time link
expect forecast pharma divis lower consensu
probabl due greater eros base sale lower xarelto limit uptak
compass higher eylea limit competiton beovu crop line
consensu sale ahead ebitda see low
reinvest merger synergi see competit advantag group
germplasm crop protect see good upsid acr like plant
corn/soy see us team ag primer consum line
consensu sale profit see increas level overal industri
crop scienc event remain confid long term replac power
pipelin strength rel peer bayer expect peak sale
potenti pipelin product would increment would
expect replac exist product support long term pa sale growth
on-going glyphos litig johnson appeal next major catalyst
bar settlement court indic march/april deadlin final oral
argument follow day period thereaft conclud appeal
updat forecast reflect fx move optim crop follow recent ag
updat xarelto sale post boost eylea sale light recent
report vascul novartiss compet drug beovu ep average
catalyst risk updat glyphos global settlement appeal court verdict
june finerinon fidelio-dkd top-line data ckd
valuat metric
price-to-earnings rel local market
number share
price rel chart measur perform
deutsch bors dax close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
share wtd average mn
ratio valuat
price book
return equiti state
net debt ebitda
price rel chart measur perform deutsch bors dax
close
spot exchang rate
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
effect exchang rate
chang net cash/debt
net debt start
chang net debt
net debt end
intang asset goodwil
total equiti liabil
result expect chang oper trend pharma key
driver perform remain xarelto eylea china newli launch
product nubeqa vitrakvi yet post materi contribut note margin
typic weaker compar first month compani comment expect
year
nubeqa whilst see nubeqa us launch disappoint far base us
rx trend uptak appar hinder need pre-identif
patient potenti sign encourag nubeqa channel
check suggest secur competit commerci coverag par
erleada well recent posit os data await detail bayer
expect roll extens free trial program month free program zero dollar
co-pay commerci patient although expect medicar access remain
limit nubeqa also recent post posit os data arami trial ahead
competitor despit start relev studi year later peer bayer
indic patient nubeqa trial less sick compar
competitor trial although note bayer /orion exclud patient
xarelto prescript trend good overal howev iqvia show
compass dose yet pick us remain less recent
script understand ex-u uptak also slow bayer comment
educ effort need increas usag also see evid
greater price competit us bayer receiv effect royalti
move bmi highlight increas rebat eliqui key
driver group overal higher rebat level rose across
full us portfolio
eylea bayer right eylea outsid us price competit
arguabl weaker much limit use label avastin account
believ around us volum recent expert call see transcript
takeaway dr paul grigg express view beovu could displac eylea
standard care signific number patient base abil dri eye
felt best predictor long term benefit also report issu
inflamm practic possibl initi inflamm resolv
second visit howev note american societi retin specialist
asr recent flag incid vascul whilst think
observ rate vascul low think observ may slow
european adopt approv expect bayer histor
cautiou growth prospect eylea given high penetr europ
go accept compound avastin use market
china annual report show market sale china
whole group believ within pharma divis
division sale bayer particip latest round tender lead
diabet drug glucobay appar undercut local tender
price cut yuan per tablet us cent time lower price
partial boost increas volum assum declin
base estim sale made specif coronaviru
assumpt lower em sale expect
pharma consum
key question pharma busi bayer replenish
pipelin forecast low singl digit sale growth
xarelto goe patent europ eylea competit step despit expect
extra us end user sale recent patent settlement xarelto
give bayer addit royalti incom period
question whether bayer would want/b abl part signific
amount cash whilst overhang expect multi-billion dollar glyphos
expect healthi growth pro-forma sale expect driver includ pre-
payment us corn seed usual tax incent buy earli pull forward
sale base higher corn price ahead season good perform
crop protect latam strong veget sale follow weak
synergi acceler compani note expect
realis end vs initi expect howev
bring forward rather increas target
drag includ on-going issu swine flu china loss herd
australian bush fire impact cotton busi although busi alreadi
flag neg impact due low water level reservoir alreadi
envisag guidanc
report ag sale see lower servic sale basf vs prior year alreadi
exclud pro-forma number
corn soy crop perform expect rebound strongli poor
plant condit earli season conting normalis weather
condit anticip cost synergi monsanto acquisit reach
expect bayer overal save expect
whilst potenti neg mix effect form greater volum uplift
less profit soy acr corn acr see larg irrelev
given overal magnitud acreag increas
assumpt result yoy forecast ebita-pr growth
global ag colleagu forecast increas corn acr plant
acr last season increas soy acr plant
acr last season recal prior us soy crop neg impact predominantli
us/china trade fear african swine fever asf demand front well
unpreced weather us spring plant season natur market
monitor potenti chines ag purchas affect coronaviru fear
though chines govern take measur improv flow feed protein
market bottom line expect materi yr/yr increas us plant soy acreag
believ risk still exist global demand front
bayer manag said expect flat corn seed price soy bean price
slightli addit discount expect february/march due
normal competit dynam ahead plant us ag team expect soy neg
mid-singl digit probabl flat corn price fairli low slightli
neg like global bayer seed/trait revenu deriv corn
soy balanc veget cotton
valu corn vs soy overal see corn profit group take
account seed trait associ crop protect understand direct sale
corn seed bring roughli doubl revenu per acr vs soy soy licens
trait highli profit believ slightli lower corn seed trait ebitda
margin base histor monsanto margin us season off-set
higher associ crop protect revenu get corn
ag team detail us primer contain market outlook seed
crop protect estim current dynam suggest corn acreag
rang soy rang depend heavili trade/asf/pl
condit follow monthli plant updat wasd data
build march usda prospect plant report march next
key forward look catalyst anticip fairli healthi end carri
estim potenti headwind price base yoy plant acreag increas
averag boost trend line yield estim uncertain demand note usda
gave initi outlook statement forecast crop year last week
corn acr soy acr
key issu stock remain on-going glyphos litig long take
settl cost could see signific ramp number glyphos
case file fy result constant recent settlement specul
like gener urgenc encourag possibl litig join mdl howev
believ well flag market could argu later file
case less like meet settlement pay-out criteria view settlement mediat
ken feinberg estim januari reuters/bloomberg jan around
roundup lawsuit could close settlement
one key question whether juri verdict appeal verdict
reach settlement johnson appeal soonest conclud
court indic march/april deadlin final oral argument follow day
period thereaft conclud appeal
unsur promot recent cancel wade case whether
reflect confidenti settlement involv parti convinc
progress made global settlement howev accord usrtk report
carey gillam sourc involv litig said certain plaintiff
agre cancel trial secur agreement specif settlement amount
parti said discuss deal conting upon success
complet larger overal settlement us litig cs assum litig
understand next trial berliant case slate start may
marin counti superior court california case grant prefer statu
expedit trial due plaintiff critic ill condit
chang earn
forecast rebound crop scienc perform conting normalis weather
come season well realis synergi integr monsanto
busi ep increas out-year reflect optim crop
busi slightli lower sale materi increas profit
synergi cost save realis monsanto integr
cut xarelto number line analyst forecast see modest
growth believ forecast also better reflect increas price competit seen
us anti-thrombot class
rais eylea forecast ahead lucenti patent expiri reflect
recent neg news flow novartiss beovu american societi retin specialist
asr flag incid vascul whilst think observ rate
vascul low think headlin risk warn asr could enough
slow usag beovu lead increas share eylea
figur chang forecast
feedback crop updat
februari bayer present updat ag portfolio present key
takeaway well note summari call
bayer clearli solid broad pipelin asset ag busi span seed
trait crop protect digit ag give us confid compani replac
power mid long term bayer expect peak sale potenti
pipelin product would increment would expect
replac exist product assum increment sale ad
would underpin division growth stabl base cs long term forecast
seed trait bayer maintain lead posit germplasm offer signific
yield advantag vs peer bu/acr advantag corn averag yield
short statur corn remain attract prospect yield advantag reduc
green-snap precis chemic applic howev question launch
could occur sooner impli graphic present
particularli given commerci pilot mexico also note clear progress
xtend soybean franchis gen product develop due resist
crop protect bayer showcas new molecul post-emerg weed control
work tough grass shown resist glyphos accompani trait
alreadi evalu xpro fungicid also present peak sale
opportun well iblon fungicid peak opportun launch
vayego broad spectrum insecticid peak opportun initi launch
geograph launch plan
digit ag advanc prescript servic deliv optimis grower decis
appear progress well commerci offer us howev
limit discuss upside/downsid risk share commerci model
discuss length ag showcas day last august note still pilot
phase updat time
highlight result read across bayer
expect global ag market grow us soybean area
product rebound weather normalis
expect rel soy corn demand continu flux grower
make ultim plant decis
anticip rebound acr go soybean accur
updat possibl march prospect plant estim publish
expect price lift corn north america ebitda tailwind due
improv mix new product see competit price soy ebitda headwind
compar bayer commentari flat corn price slightli lower soy price
also mention cost implement erp enterpris resourc
plan system well royalti assum vast major go
bayer
food feed biofuel need
world pop
meat develop nation need
reduct arabl land per capita need
ha ag land loss annual
climat chang make harder reach demand innov key
long term demand grain continu grow
invest
still plenti room improv product gain
convert invest product doubl spend
next closest competitor invest next decad
 employe countri choic global
pursu increment improv seed
increment improv less import disrupt improv
farmer need preserv yield exist crop
non risk adjust peak sale product develop product germplasm
account half
sale increment sale new technolog
corn
soy
cereal
new crop protect formul advanc
short statur corn present pipelin question take long
gen pest control soy
new hybrid provid yield advantag prior gener
corn hybrid largest divers germplasm
lead posit key corn market expect grow lead
bushel per acr advantag corn compar lead competitor
us bu/ac europ mexico south africa brazil argentina
advers weather event affect product develop built corn product
design center marana arizona come on-line next month
bring part breed process indoor doubl breed gener
acceler develop marana az centr come line next month
breed biotech approach short-statur corn advanc phase gene edit
version short-statur corn come
vitala short statur corn hybrid commerci beta mexico
reduc crop loss less green snap lodg annual yield loss
precis use crop input applic support in-season crop protect
fertilis applic
increas environment sustain optimis use nitrogen land water
global opportun corn acr america account acr alon
pairwis plant base edit technolog next gen edit capabl
use tool see tangibl respons
trait work qualiti trait diseas resist trait stress toler plant
growth develop
xtendflex next gen soybean
yield perform consist roundup readi xtend soybean
inclus low volatil dicamba system soy offer day
increas spectrum control weed speci enlist control
residu soil activ control weed yet emerg time spring
expect us acr limit spring often case first year anticip
high demand long term
gen soybean come next decad offer addit toler
soy herbicid class plu ppo
intacta xtend broaden insect weed control spectrum
intacta allow till farm reduc insecticid spray reduc water usag carbon
addit mode action insect control
intacta soybean wide adopt acr season
lygu thrip control trait launch
opportun us
expect broadli licens trait
time candid discoveri sinc
increment improv
includ asian soy bean rust protect best formul innov agro award
reduc target loss
potenti reach annual sale
phase next gen supra
new zealand launch expand europ peak potenti
launch plan
asia focu initi launch korea
versatil broad spectrum pest crop
benefici work tough grass shown resist glyphos
alreadi trait evalu go
advanc phase earli develop
acr potenti corn soy wheat
partner fieldview platform
data lead improv recommend grower
first connect hour data took month collect second hour
data took month collect
planter sprayer upload data sinc jan
algorithm use plant breed data fieldview data optim grower decis
test show use tool improv yield bu/ac
beta launch corn state
plan launch soy equival middl decad
expect launch latam
fieldview seed script commerci offer us
yield benefit bu/ac beta launch brazil argentina europ
 addit gene edit short-statur corn gene edit suppos abl move
pipelin faster scienc basi regulatori basi faster
believ move product gene edit quickli depend geographi
though need match trait packag look take market segment
effici discoveri process take time earli phase depend
regulatori system evolv hurdl could lower depend major regulatori agenc
 xtendflex soybean valu proposit preval increment weed key
product across north american market expect grower use
variou option differ give grower abil use chemic
offer complementari mode action dicamba offer differ opportun glyphos
 veget seed busi gene edit avoid gmo stigma updat use gene
edit busi
look gene edit overal regulatori environ complex see posit
develop around world gene edit regul
 corn seed advisor yield bump mechan drive market share gain
increas yield help get market share still look busi model
share revenu custom
 number pipelin advanc seem much higher monsanto bayer
stand-alone basi merger benefit
number fluctuat year year huge number project portfolio advanc eb
flow year real qualiti advanc
 xtendflex price premium regular xtend
havent finalis price yet look premium price innov
take hint extend flex cotton
 nemastrik announc would offer updat
technic team continu work formul could re-launch product follow
year continu work formul side dont intend market
 increment sale captur chang price model commerci
perspect mid long term
half pipelin estim replac sale increment
mean build market share increment part pipelin precis model
differ life cycl product product reach peak year
year year averag time peak sale
 plant chang eat habit chang meat/less veg
excit increas interest plant-bas protein consum lot interest
sustain bayer largest plant protein compani assum time decreas decreas
per capita consumpt meat time pop increas next
decad net net increas demand meat primarili driven asia see
increas demand meat feed also plant protein think well
posit tap grow potenti
 short statur corn basf get piec profit pie valu share compon
one version joint collabor basf royalti commercialis
 short-statur corn differ yield differ version develop
default yield isnt better wors make crop shorter open opportun
higher plant densiti less green snap lodg price chemic applic think
drive yield unpreced way
 benefit lower fertilis applic short statur corn
short statur corn doesnt chang plant use nitrogen allow precis applic
 multi soy herbicid trait trait resist weed
balanc stay ahead versu weed develop resist differ herbicid
prove overal toolbox option grower
number fact actual work complementari fashion cover
effici
 colour new herbicid molecul earli develop could replac
new mode action post emerg treatment addit complementari solut think
glyphos continu provid valu year grower need addit mode
action new mode action complementari provid resist glyphos resist
paid acr last year seed advisor seed script tool beta south
america come year intang benefit relationship custom
transpar perform competitor custom appreci
 go forward think balanc sale trait licens stay
broadli think new trait uniqu high margin trait
dont expect royalti incom go majorli continu innov ensur
keep royalti incom dont expect major increas decreas
 give us idea servic farmer pay term paid
acr see time line adopt higher valu ad prescript servic
make recommend share upsid higher yield
pilot us year combin new busi model opportun lot
learn put learn new pilot expand number acr
test share upside/downsid risk see lot interest risk share
downsid upsid still learn pilot phase
bayer us end user sale restat exclud oper item rate net net share except ep ops- special item inc special item per charl martineau pm univers toronto februari
compani mention price
